EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Loss of CELF2 promotes skin tumorigenesis and increases drug resistance

Bindeshwar Sah, Jasvinder Singh, Yao Shen, Noah Goldfarb, Faramarz H Samie, Larisa J Geskin, Liang Liu iD

International Journal of Dermatology · 2025

DOI: 10.1111/ijd.17295 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Dermatology, 2025. Verfasst von Bindeshwar Sah und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Hormel Institute, University of Minnesota, Austin, MN, USA. Hauptthemen laut MEDLINE: Skin Neoplasms, Carcinoma, Squamous Cell, Drug Resistance, Neoplasm, Cell Proliferation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CELF2 belongs to the CELF RNA‐binding protein family and exhibits antitumor activity in various tumor models. Analysis of the pan‐cancer TCGA database reveals that CELF2 expression strongly correlates with favorable prognosis among cancer patients. The function of CELF2 in nonmelanoma skin cancer has not been studied.

Methods

We used shRNA‐mediated knockdown (KD) of CELF2 expression in human squamous cell carcinoma (SCC) cells to investigate how CELF2 impacted SCC cell proliferation, survival, and xenograft tumor growth. We determined CELF2 expression in human SCC tissues and adjacent normal skin using immunofluorescence staining. Additionally, we investigated the changes in CELF2 and its target gene expression during UV‐induced and chemical‐induced skin tumorigenesis by western blotting.

Results

CELF2 KD significantly increased SCC cell proliferation, colony growth, and SCC xenograft tumor growth in immunodeficient mice. CELF2 KD in SCC cells led to activation of KRT80 and GDF15, which can potentially promote cell proliferation and tumor growth. While control SCC cells were sensitive to anticancer drugs such as doxorubicin, SCC cells with CELF2 KD became resistant to drug‐induced tumor growth retardation. Finally, we found CELF2 expression diminished during both UV‐ and chemical‐induced skin tumorigenesis in mice, consistent with reduced CELF2 expression in human SCC tumors compared to adjacent normal skin.

Conclusion

This study shows for the first time that CELF2 loss occurs during skin tumorigenesis and increases drug resistance in SCC cells, highlighting the possibility of targeting CELF2‐regulated pathways in skin cancer prevention and therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin NeoplasmsCarcinoma, Squamous CellDrug Resistance, NeoplasmCell ProliferationCELF ProteinsHumansAnimalsMiceCell Line, TumorCarcinogenesisGene Knockdown TechniquesDoxorubicinUltraviolet RaysNerve Tissue ProteinsRNA, Small InterferingSkinAntibiotics, AntineoplasticXenograft Model Antitumor AssaysGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

CELF2RNA‐binding proteinSCCUV radiationskin cancersquamous cell carcinomatumor

Substanzen

CELF ProteinsCELF2 protein, humanDoxorubicinNerve Tissue ProteinsRNA, Small InterferingAntibiotics, Antineoplastic

Autor:innen und Institutionen

  • The Hormel Institute, University of Minnesota, Austin, MN, USA.
  • Department of Systems Biology, Columbia University Irving Medical Center, New York, NY, USA.
  • Department of Internal Medicine and Dermatology, University of Minnesota, Minneapolis, MN, USA.
  • Minneapolis VA Medical Center Health Care System, Minneapolis, Minnesota, USA.
  • Department of Dermatology, Columbia University Irving Medical Center, New York, NY, USA.
  • Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.

ORCID-Profile: Liang Liu

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Sah, B., Singh, J., Shen, Y., Goldfarb, N., Samie, F. H., Geskin, L. J., & Liu, L. (2025). Loss of CELF2 promotes skin tumorigenesis and increases drug resistance. International Journal of Dermatology. https://doi.org/10.1111/ijd.17295

Vancouver

Sah B, Singh J, Shen Y, Goldfarb N, Samie FH, Geskin LJ, et al. Loss of CELF2 promotes skin tumorigenesis and increases drug resistance. International Journal of Dermatology. 2025. doi:10.1111/ijd.17295

BibTeX
@article{Sah2025,
  author = {Sah, Bindeshwar and Singh, Jasvinder and Shen, Yao and Goldfarb, Noah and Samie, Faramarz H and Geskin, Larisa J and Liu, Liang},
  title = {Loss of CELF2 promotes skin tumorigenesis and increases drug resistance},
  journal = {International Journal of Dermatology},
  year = {2025},
  doi = {10.1111/ijd.17295}
}
Kostenlos starten →